Pfizer wins in London court, invalidates GSK’s respiratory syncytial virus vaccine patent
Pfizer Inc. (NYSE:PFE) stock rose on Monday, with session volume at 31.16 million, according to data from Benzinga Pro.
Activist investor Starboard Value has invested about $1 billion in Pfizer as the pharmaceutical giant grapples with weak demand for its COVID-19 vaccines and treatments.
In another positive development, Pfizer won a bid in a London court to invalidate two patents from GSK Plc (NYSE:GSK) for its respiratory syncytial virus (RSV) vaccine.
Also read: UK chooses Pfizer over GSK for multi-million dose RSV vaccine deal.
Pfizer and GSK are competing to enter the respiratory syncytial virus (RSV) vaccine market, which could be worth more than $10 billion by 2030.
In August 2023, GSK sued Pfizer in Delaware state court, alleging that Pfizer’s RSV vaccine Abrysvo infringed four patents on GSK’s RSV vaccine Arexvy.
In the lawsuit, GSK said Pfizer began working on the RSV program in 2013, at least seven years after GSK.
The European pharmaceutical giant also said that Pfizer has known about the ‘002 patent (named Recombinant RSV Antigen) since at least October 2019. At this time, Pfizer filed an opposition with the European Patent Office, claiming a European counterpart to the ‘002 patent. is invalid.
In June 2022, Pfizer also filed a lawsuit against GSK in the Royal Courts of Justice in London, claiming that the European patents corresponding to the ‘002 and ‘239 patents (RSV F protein compositions and methods of manufacture) are invalid. filed a lawsuit.
The suit says Pfizer has known about GSK’s patented technology since at least 2019, when it began challenging the validity of the European patent.
Reuters noted that a GSK spokesperson said the ruling “does not impact our ability to launch and market Arexvy worldwide, including in the UK.” The company believes that Pfizer infringed its patents, remains confident in the validity of its patents, and plans to appeal this decision.
In response, Pfizer expressed satisfaction with the court’s decision. A spokesperson said: “Pfizer is pleased with the UK High Court’s decision that certain GSK patents relating to RSV technology are invalid and not infringed.”
Price Action: At last check on Monday, GSK stock was up 0.06% at $38.85 and PFE stock was up 2.38% at $29.26.
Read next:
Photo credit: Shutterstock
Unlock: 5 new deals every week. Click now to get our top trading ideas every day, plus unlimited access to cutting-edge tools and strategies to help you stay ahead of the market.
story continues
Want the latest stock analysis from Benzinga?
This article was originally published as Pfizer wins in London court, invalidates GSK’s respiratory syncytial virus vaccine patent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. Unauthorized reproduction is prohibited.
